BioPharm International - Articles on bioprocessing methods, regulatory compliance, and biotech strategies
ASBPE

ADVERTISEMENT

Online Exclusive

What Can Biotech Learn From Toyota's Recalls?
FindPharma
Featured Jobs

More Jobs

Author Guidelines
Previous StoryPlay / PauseNext Story
Podcast: Efficient and Effective Approaches to Managing Raw Material Methods
Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products
Podcast: 2012 Retrospective on Separations Technology
Podcast: Sutro Biopharma's Trevor Hallam offers a glimpse into the future of drug design
Podcast: Strong Product Differentiation

From the Editor
Some Supply Chain Lessons Can Go a Long Way

Compliance Notes
How to Respond to Consent Decrees

Perspectives on Outsourcing
Channeling Steve Jobs

Burrill on Biotech
A Strong Start to 2012

Final Word
A New Way to Think About Outsourcing Partnerships

FDA expands use for FilmArray Respiratory Panel
FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
FDA proposal aims to help reduce unnecessary radiation exposure for children
FDA issues final rule on sterility testing of biological products
FDA permits marketing of a new device for abdominal surgery

Big Pharma Bands with Academia in $23-Million Deal
May 17, 2012
US Senators Probe Links Between Opiod Manufacturers and Medical Groups
May 16, 2012
CDER Ombudsman Releases Annual Report
May 15, 2012
GlaxoSmithKline Moves Forward with $2.6 Billion Offer for Human Genome Sciences
May 14, 2012
EFPIA Advances Medicines Verification Project
May 10, 2012
FDA Explores Options to Expand Access to NonPrescription Drugs
Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.
BioPharm International - May 1, 2012
Manufacturers Wrestle with Drug Abuse and Critical Shortages
Soaring opioid use creates challenges for new drug development and supply-chain control.
BioPharm International - April 1, 2012
Communications Advances Present Challenges to Manufacturers
Social media use raises questions about applying old standards to new information technology.
BioPharm International - March 1, 2012
Weekly Poll
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
10%
Greater adoption of continuous manufacturing
10%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
20%
The rise of biologic-based drugs in commercial product portfolios and pipelines
50%
Greater adoption of the preferred provider model in outsourcing
10%
View Results
Managing Cell Based Potency Assays-from Development to Lifecycle Maintenance
May 1, 2012
Size-Exclusion Ultra Performance Liquid Chromatography for the Analysis of Covalent High Molecular Weight Insulin
April 25, 2012
Bio-G Whitepaper: Biomanufacturing Debottlenecking and Process Optimization
April 25, 2012
Implementation of Mustang® Q Membrane Chromatography
March 27, 2012
Separation of Schizandrin, Schizandrin A, and Schizandrin B in a Tablet Sample
March 27, 2012
Click here